Received Apr 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | OT |
exposed to HPV following their first dose of GARDASIL 9; a patient who missed their second dose of GARDASIL 9; This spontaneous report was received from a pharmacist and refers to a 27-year-old male patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. In October 2024, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (0.5ml/dose), administered by Intramuscular route (strength, lot # and expiration date were not reported) for prevention of human papillomavirus (HPV)-related disease. On an unknown date, the patient missed his second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (Vaccine dose omission) and was exposed to HPV following his first dose of suspect vaccine. The reporter could not confirm if patient has contracted HPV following exposure. No symptoms reported. At the reporting time, the outcome of exposed to HPV was unknown. The action taken with suspect vaccine was not applicable (conflicting information: also reported as dose not changed). The causal relationship between the event of exposed to HPV and suspect vaccine was not provided. Lot# is being requested and will be submitted if received.